USDA confirmed highly pathogenic Avian influenza in Alaska
On Apr. 30, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
-
-
Moderna finalized plan for long-term strategic partnership with the Government of Canada
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
-
USDA confirmed highly pathogenic Avian influenza in Vermont
On Apr. 29, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
-
Moderna filed for authorization of Its COVID-19 vaccine in young children six months to under six years of age
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
-
WHO reported Ebola virus disease in Democratic Republic of the Congo
On Apr. 28, 2022, the Ministry of Health of the Democratic Republic of the Congo declared an outbreak…
-
U.S. case of Human avian influenza A(H5) virus reported
On Apr. 28, 2022, Centers for Disease Control and Prevention (CDC) reported that a person had tested positive…
-
USDA issued a conditional license for mink Coronavirus Vaccine
On Apr. 27, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service announced it had…
-
Human Avian H3N8 infection confirmed in Henan province
On Apr. 26, 2022, China’s National Health Commission reported a case of human infection with H3N8 avian influenza…
-
Pfizer and BioNTech submitted application for U.S. EUA for COVID-19 vaccine booster dose in children 5 through 11 years of age
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
-
Veklury (Remdesivir) was first and only approved treatment for pediatric patients under 12 years of age with COVID-19
On Apr. 25, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental…
-
Novavax announced initiation of COVID-19 vaccine booster study in adolescents in phase 3 PREVENT-19 trial
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
-
WHO recommended Paxlovid for high-risk COVID patients
On Apr. 22, 2022, the World Health Organization (WHO) made a strong recommendation for nirmatrelvir and ritonavir, sold…
-
Initial results from Novavax’ COVID-19-Influenza vaccine trial were first to show feasibility of combination vaccine
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
-
Codiak announced new preclinical data supporting development of broadly protective pan beta-Coronavirus vaccine
On Apr. 20, 2022, Codiak BioSciences announced announc a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of…
-
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…
-
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
-
COVID-19 booster effectiveness remained high during Omicron surge
On Apr. 18, 2022, the Military Health System reported that active-duty service members who received a COVID-19 vaccine…
-
FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines
On Apr. 18, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) of…
-
Idaho officials confirmed highly pathogenic Avian influenza
On Apr. 15, 2022, The Idaho State Department of Agriculture (ISDA) announed it had received confirmation of multiple…
-
Pfizer and BioNTech data demonstrated high immune response following booster dose of COVID-19 vaccine in children 5 through 11 years of age
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
-
Regeneron antibody cocktail approved by European Commission to treat and prevent COVID-19
On Nov. 12, 2021, Regeneron announced that the U.S. Food and Drug Administration had extended by three months…
-
FDA authorized first COVID-19 diagnostic test using breath samples
On Apr. 14, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
-
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
-
Highly pathogenic avian influenza reported in Alberta
On Apr. 12, 2022, the Province of Alberta poultry reported that farms had tested positive for highly pathogenic…
-
Novavax and Serum Institute of India received EUA for COVID-19 vaccine in Thailand
On Apr. 8, 2022, Novavax announced and Serum Institute of India (SII), the world’s largest vaccine manufacturer by…
-
IAVI and Moderna partnered to tackle broad global health priorities using mRNA for vaccines and antibodies
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
-
NIH funded new tuberculosis research advancement centers
On Apr. 6, 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes…
-
USDA confirmed highly pathogenic Avian influenza in Texas
On Apr. 3, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
-
Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced data evaluating LAGEVRIO (molnupiravir), an investigational oral antiviral COVID-19…
-
Ivermectin ineffective in large study of treatment among patients with Covid-19
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
